Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan plus pembrolizumab as adjuvant treatment in renal cell carcinoma
NL-OMON60872Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Belzutifan plus pembrolizumab with Placebo plus pembrolizumab (2 arms). Primary endpoint: Disease-Free Survival. Started Apr 2022; status: active, not recruiting.
02
Drugs
belzutifanpembrolizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON60872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60872.